Novo Nordisk has officially launched its blockbuster weight-loss and diabetes drug Ozempic in India, pricing the starter dose at just $24.35 per week, a move that underscores the intensifying global race for dominance in the fast-growing obesity treatment market.
The Danish pharmaceutical giant announced that Ozempic will be sold in injectable pens in India, available in 0.25mg, 0.5mg and 1mg strengths. Each pen contains four weekly doses, offering a once-a-week treatment option that has reshaped diabetes and weight-loss care worldwide.
Under the new pricing structure, the 0.25mg dose costs ₹8,800 ($97) per month, while the 0.5mg dose is priced at ₹10,170. The 1mg version will retail at ₹11,175 per month, making India one of the most affordable markets globally for the drug.
Originally approved by the US Food and Drug Administration in 2017 for the treatment of Type 2 diabetes, Ozempic has surged in popularity due to its appetite-suppressing effects, leading to significant weight loss. Novo Nordisk says the drug also delivers added benefits for patients with cardiovascular and kidney conditions.
“Ozempic helps people with diabetes lose up to eight kilograms, meaning its benefits go beyond glucose control alone,” said Vikrant Shrotriya, corporate vice president and managing director of Novo Nordisk India.
Why the launch matters to the Gulf
The India rollout comes as Ozempic and rival drugs such as Mounjaro continue to influence lifestyle trends across the Gulf, including changes in dining habits, wellness spending and healthcare demand. In the UAE and wider region, GLP-1 weight-loss injections have already reshaped conversations around obesity, diabetes and preventive care.
India’s launch at a significantly lower price point highlights the growing divide between global markets — and raises questions about future pricing strategies in the Middle East as competition increases.
India: A high-stakes market
India has the second-largest population of people living with Type 2 diabetes, after China, and is experiencing steadily rising obesity levels. This has turned the country into a critical battleground for pharmaceutical companies seeking a share of what analysts estimate could become a $150-billion-a-year global weight-loss drug market by the end of the decade.
Novo Nordisk’s decision to move early in India is widely seen as a strategic play to establish market leadership before domestic drugmakers introduce cheaper alternatives. Patents for semaglutide — the active ingredient in Ozempic and Wegovy — are set to expire in March 2026, paving the way for locally manufactured versions.
As demand for medical weight-loss solutions accelerates across Asia and the Gulf, India’s low-cost launch could signal a new phase in how obesity and diabetes treatments are priced, accessed and debated worldwide.
